Briggs Morrison - 01 Apr 2022 Form 4/A - Amendment Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: President, Head of R&D, Director
Signature: /s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol: SNDX
Transactions as of: 01 Apr 2022
Net transactions value: +$530,446
Form type: 4/A - Amendment
Filing time: 13 Apr 2022, 16:09:25 UTC
Date Of Original Report: 05 Apr 2022
Previous filing: 03 Feb 2022
Next filing: 18 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNDX	Common Stock	Options Exercise	$507,924	+70,545	+396%	$7.20	88,381	01 Apr 2022	Direct	F1
transaction	SNDX	Common Stock	Options Exercise	$22,522	+3,128	+18%	$7.20	20,964	04 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Options Exercise	$0	-70,545	-100%	$0.000000^*	0	01 Apr 2022	Common Stock	70,545	$7.20	Direct	F1, F2
transaction	SNDX	Stock Options (Right to buy)	Options Exercise	$0	-3,128	-100%	$0.000000^*	0	04 Apr 2022	Common Stock	3,128	$7.20	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date.
F2	This option is fully vested.